Misplaced Pages

Anteris Technologies

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Australian biotechnology company

Anteris Technologies Limited
Formerly
  • Allied Healthcare Group (2011–2013)
  • Admedus (2013–2020)
Company typePublic
Traded asASX: AVR
IndustryBiotechnology
HeadquartersToowong, Australia
Websiteanteristech.com

Anteris Technologies Limited is an Australian biotechnology company.

History

Anteris originates from the merger of Allied Medical and BioMD. Allied Medical was a company spun out of mining company Fortescue Metals Group in 2005 which focused on selling medical equipment such as catheters. It entered the biotechnology space in July 2010 when it purchased a 38.6 per cent stake in Brisbane-based Coridon for A$3 million. By February 2011, its stake increased to 55 per cent. In February 2011, Allied Medical agreed to a reverse takeover deal with BioMD, a listed biotech company. The takeover was completed in June 2011 resulting in the combined company, Allied Healthcare Group, listing on the Australian Securities Exchange (ASX).

In September 2012, Allied raised $10.4 million to launch CardioCel across Europe. In November 2013, Allied Healthcare changed its name to Admedus. In December 2013, Admedus purchased a manufacturing site in Malaga to scale-up production of CardioCel and support the development and manufacture of additional regenerative tissue products.

In October 2019, Admedus sold its CardioCel and VascuCel patch business to U.S.-based LeMaitre Vascular. Under the agreement, Admedus received A$22.8 million upfront followed by deferred payments of $1 million each at 12 months and at 36 months. Additionally, the company could receive up to $11.4 million in earn-out payments. Admedus retained the right to manufacture CardioCel and VascuCel products at its Malaga facility for LeMaitre over the following three years. In May 2020, Admedus changed its name to Anteris Technologies.

References

  1. Thomson, James (18 July 2010). "Medical company backed by mining billionaire Andrew Forrest launches biotech investment push". SmartCompany. Retrieved 14 March 2023.
  2. Greenblat, Eli (18 July 2010). "Mining magnate invests in biotech". The Sydney Morning Herald. Retrieved 15 March 2023.
  3. ^ Evans, Nick (15 February 2011). "Forrest biotech company to list". PerthNow. Retrieved 15 March 2023.
  4. Evans, Nick (31 May 2011). "BioMD's Allied takeover wrapping up soon". PerthNow. Retrieved 15 March 2023.
  5. Stafford, Patrick (20 June 2011). "Andrew Forrest-backed biotech lists on ASX". SmartCompany. Archived from the original on 24 June 2011. Retrieved 15 March 2023.
  6. "bioMD Limited Makes Offer for Unlisted Allied Medical to Create Diversified Healthcare Group" (Press release). BioSpace. 15 February 2011. Retrieved 16 March 2023.
  7. ^ Drummond, Cameron (12 December 2013). "Biotech company buys manufacturing facility". Business News. Retrieved 15 March 2023.
  8. Smith, Sean (21 November 2013). "Allied rebrands as Admedus". The West Australian. Retrieved 15 March 2023.
  9. ^ "Admedus sells its CardioCel and VascuCel patch business for $A36.2m". Australian Manufacturing. 16 October 2019. Retrieved 15 March 2023.
  10. Ford, Omar (14 October 2019). "Admedus Turns Attention to TAVR Program". mddionline.com. Retrieved 15 March 2023.
  11. Anderson, Caitlin (21 February 2023). "Med-device company Anteris Technologies raises $24 million". www.bizjournals.com. Retrieved 8 August 2024.

External links

Categories: